FrancophonIA/ELRC3.0 huggingface dataset:
English: There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues.
Slovenian: Opisani so primeri motenega delovanja mitohondrijev pri dojenčkih, ki so bili in utero in/ali po rojstvu izpostavljeni nukleozidnim analogom.
English: In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml compared to a median increase of 0.3 log10 copies/ml in those patients receiving lamivudine monotherapy.
Slovenian: V dvojno slepi študiji pri bolnikih s kroničnim hepatitisom B z YMDD mutantom HBV in kompenzirano boleznijo jeter (NUC20904) z zmanjšanim virološkim in biokemičnim odzivom na lamivudin (n=95) je dodajanje 10 mg adefovirjevega dipivoksila enkrat dnevno k obstoječi uporabi 100 mg lamivudina v času 52 tednov povzročilo povprečno znižanje HBV DNA za 4,6 log10 kopij/ml v primerjavi s povprečnim zvečanjem HBV DNA za 0,3 log10 kopij/ml pri bolnikih, ki so bili zdravljeni samo z lamivudinom.
English: • medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly
Slovenian: • redna uporaba zdravil (večinoma tekočine), ki vsebujejo sorbitol ali druge sladkorne alkohole (npr. ksilitol, manitol, laktitol, maltitol),
English: A comparison of post-treatment ALT elevations between weeks 52 and 68 in patients who discontinued lamivudine at week 52 and patients in the same studies who received placebo throughout the treatment course is shown in Table 3.
Slovenian: V preglednici 3 je prikazano zvišanje ALT po zdravljenju med 52. in 68. tednom pri bolnikih, katerim so v 52. tednu ukinili lamivudin, v primerjavi z bolniki v isti študiji, ki so celo obdobje zdravljenja dobivali placebo.
English: Patients with ALT Elevation/ Patients with Observations*
Slovenian: Bolniki z zvišano aktivnostjo ALT/ Opazovani bolniki* Lamivudin
English: EU/1/99/114/002 84 tablets
Slovenian: EU/1/99/114/001 28 tablet EU/1/99/114/002 84 tablet
English: The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA (23/209, 11 %) compared to those without detectable YMDD mutant HBV (11/221, 5 %).
Slovenian: Obseg celokupnega napredovanja bolezni je bil v skupini, ki je prejemala lamivudin, večji pri osebah z zaznavnim YMDD mutantom HBV DNA (23/209, 11 %) v primerjavi s tistimi, pri katerih YMDD mutant HBV ni bil zaznaven (11/221, 5 %).
English: 84 film-coated tablets
Slovenian: 28 filmsko obloženih tablet 84 filmsko obloženih tablet
English: Lamivudine-TP does not interfere with normal cellular deoxynucleotide metabolism.
Slovenian: Lamivudin-TP ne vpliva na normalno presnovo celičnih deoksinukleotidov.
English: Therefore, the concomitant use of lamivudine with cladribine is not recommended (see section 4.4).
Slovenian: Sočasna uporaba lamivudina in kladribina zato ni priporočljiva (glejte poglavje 4.4).
English: United Kingdom or
Slovenian: United Kingdom
English: However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary.
Slovenian: Če bolnik nima oslabljenega delovanja ledvic, odmerka lamivudina kljub temu ni treba prilagajati.
English: Development of YMDD mutant HBV is associated with reduced treatment response in some patients, as evidenced by increased HBV DNA levels and ALT elevations from previous on-therapy levels, progression of signs and symptoms of hepatitis disease and/or worsening of hepatic necroinflammatory findings.
Slovenian: Pojav YMDD mutanta HBV je povezan z zmanjšano odzivnostjo na zdravljenje pri nekaterih bolnikih, ki se kaže kot povečanje vrednosti HBV DNA in vrednosti ALT glede na prejšnje vrednosti med zdravljenjem, kot poslabšanje znakov in simptomov hepatitisa in/ali poslabšanje nekroznih in vnetnih sprememb jeter.
English: Furthermore, lamivudine-TP has little effect on mammalian cell DNA content.
Slovenian: Lamivudin-TP ima majhen učinek na vsebnost celične DNA pri sesalcih.
English: What Zeffix looks like and contents of the pack
Slovenian: Izgled zdravila Zeffix in vsebina pakiranja
English: What you need to know before you take Zeffix Do not take Zeffix:
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Zeffix Ne jemljite zdravila Zeffix
English: Talk to your doctor if any of these apply to you.
Slovenian: Posvetujte se z zdravnikom, če kar koli od tega velja za vas.
English: Allergic reaction These are rare (may affect up to 1 in 1,000 people).
Slovenian: Te so redke (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
English: Film-coated tablet:
Slovenian: Filmsko obložene tablete:
English: Therapy with Zeffix should be initiated by a physician experienced in the management of chronic hepatitis B.
Slovenian: Zdravljenje z zdravilom Zeffix mora uvesti zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa B.
English: The recommended dosage of Zeffix is 100 mg once daily.
Slovenian: Priporočeni odmerek zdravila Zeffix je 100 mg enkrat dnevno.
English: • skin rash or ‘hives' anywhere on the body
Slovenian: • krči in bolečine v mišicah • kožni izpuščaji ali ‘koprivnica' kjerkoli po telesu
English: Therefore breastfeeding may be considered in breastfeeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Slovenian: Zato ženske, ki prejemajo lamivudin zaradi HBV, lahko dojijo, vendar je treba pri odločitvi o tem upoštevati koristi dojenja za otroka in koristi zdravljenja za žensko.
English: • swelling of eyelids, face or lips
Slovenian: Med znaki so: • oteklina očesnih vek, obraza ali ustnic
English: Therefore, following HBeAg seroconversion, patients should be periodically monitored to determine that serologic and clinical responses are being maintained.
Slovenian: Po serokonverziji HBeAg torej priporočamo občasno preverjanje ali sta se serološki in klinični odziv ohranila.
English: Lamivudine is predominately cleared by renal excretion of unchanged substance.
Slovenian: Lamivudin se v glavnem izloča preko ledvic v nespremenjeni obliki.
English: The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13 % (12/95) for placebo versus 22 % (42/191) for lamivudine; p=0.057).
Slovenian: Pri tej populaciji razlika v odstotkih serokonverzije HBeAg (izginotje HBeAg in HBV DNA ter pojav protiteles HBeAb) med placebom in lamivudinom ni bila statistično signifikantna (po enem letu je bila 13 % (12/95) za placebo v primerjavi z 22 % (42/191) za lamivudin; p = 0,0057).
English: The other ingredients are: sucrose, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), citric acid, propylene glycol, sodium citrate, artificial strawberry flavour, artificial banana flavour, purified water.
Slovenian: Pomožne snovi so: saharoza, metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216), citronska kislina, propilenglikol, natrijev citrat, umetna aroma jagode, umetna aroma banane, prečiščena voda.
English: 2 Upper limit of normal
Slovenian: Zgornja meja normale
English: The majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system).
Slovenian: Lamivudin se večinoma izloča v urin nespremenjen preko glomerularne filtracije in aktivne sekrecije
English: • In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Slovenian: • Pri HBeAg negativnih (pre-core mutanta) bolnikih s CHB brez ciroze je treba zdravljenje nadaljevati vsaj do HBs serokonverzije ali do pojava znakov izgube učinkovitosti.
English: Zeffix film-coated tablets are supplied in tamper evident foil blisters containing 28 or 84 tablets.
Slovenian: Zeffix filmsko obložene tablete so na voljo v škatlah, ki vsebujejo 28 ali 84 tablet v pretisnih omotih z zaščito, ki dokazuje, da še niso bile odprte.
English: Each film-coated tablet contains 100 mg of lamivudine.
Slovenian: Vsaka filmsko obložena tableta vsebuje 100 mg lamivudina.
English: Lamivudine has been administered to children (2 years and above) and adolescents with compensated chronic hepatitis B. However, due to limitations of the data, the administration of lamivudine to this patient population is not currently recommended (see section 5.1).
Slovenian: Pediatrični bolniki Lamivudin se je uporabljal pri otrocih (2 leti in starejši) in mladostnikih s kompenziranim kroničnim hepatitisom B. Vendar uporaba lamivudina v tej populaciji bolnikov, zaradi omejenih podatkov,
English: Keep in touch with your doctor, and don't stop taking Zeffix without your doctor's advice.
Slovenian: Bodite v stiku z zdravnikom in ne nehajte jemati zdravila Zeffix, če vam tega ne svetuje zdravnik.
English: GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com
Slovenian: GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-med-info@gsk.com
English: The other ingredients are: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hypromellose, titanium dioxide, macrogol 400, polysorbate 80, synthetic yellow and red iron oxide.
Slovenian: hipromeloza, titanov dioksid, makrogol 400, polisorbat 80, sintetični rumeni in rdeči železov oksid.
English: Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity.
Slovenian: Pri študijah toksičnosti na živalih dajanje velikih odmerkov lamivudina ni bilo povezano s toksičnostjo za kakšen pomemben organ.
English: In order to reduce the risk of resistance in patients receiving lamivudine monotherapy, a switch to or addition of an alternative agent without cross-resistance to lamivudine based on therapeutic guidelines should be considered if serum HBV DNA remains detectable at or beyond 24 weeks of treatment (see section
Slovenian: Da bi zmanjšali tveganje odpornosti pri bolnikih, ki prejemajo monoterapijo z lamivudinom, je treba skladno s smernicami za zdravljenje razmisliti o zamenjavi ali dodatku drugega zdravila, ki nima navzkrižne odpornosti proti lamivudinu, če je HBV DNA v serumu zaznana po 24 ali več tednih zdravljenja
English: • an increase in the level of an enzyme produced in the muscles (creatine phosphokinase) which may be a sign that body tissue is damaged.
Slovenian: • zvišana vrednost encima, ki nastaja v mišicah (kreatin-fosfokinaze); to je lahko znak okvare telesnega tkiva.
English: In patients with YMDD mutant HBV, 18/39 (46 %) had improvements in necroinflammatory activity and 9/39 (23 %) had worsening.
Slovenian: Pri bolnikih z YMDD mutantom HBV je pri 18/39 (46 %) prišlo do izboljšanja nekrotičnih in vnetnih sprememb, pri 9/39 (23 %) pa do poslabšanja.
English: Side effects thought to be caused by Zeffix
Slovenian: Neželeni učinki, ki bi lahko bili povezani z jemanjem zdravila Zeffix
English: This reaction may be delayed.
Slovenian: Alergijska reakcija je lahko odloženega tipa.
English: Zeffix oral solution is supplied in cartons containing a white polyethylene bottle, with a child resistant cap.
Slovenian: Zeffix peroralna raztopina je na voljo v škatlah v katerih je bela polietilenska plastenka, z za otroke varno zaporko.
English: How much to take The usual dose of Zeffix is 20 ml (100 mg lamivudine) once a day.
Slovenian: Koliko zdravila vzeti Običajni odmerek zdravila Zeffix je 20 ml (100 mg lamivudina) enkrat dnevno.
English: How much to take The usual dose of Zeffix is one tablet (100 mg lamivudine) once a day.
Slovenian: Koliko zdravila vzeti Običajni odmerek zdravila Zeffix je ena tableta (100 mg lamivudina) enkrat dnevno.
English: See the diagram and instructions after section 6 of this leaflet for how to measure and take a dose of medicine.
Slovenian: Za informacije kako meriti odmerek in jemati zdravilo glejte skico in navodila na koncu poglavja 6 tega navodila za uporabo.
English: Cladribine
Slovenian: Kladribin
English: Lamivudine induces early embryolethality when administered to pregnant rabbits at exposure levels comparable to those achieved in man, but not in the rat even at very high systemic exposures.
Slovenian: Po izpostavitvi brejih kunčic koncentracijam lamivudina, ki so primerljive s tistimi, doseženimi pri človeku, pride do zgodnjega embrionalnega pogina, do slednjega pa ne pride pri podganah in to kljub zelo visoki sistemski izpostavljenosti.
English: HBeAg seroconversion was increased in patients with elevated ALT levels; 77 % (20/26) of patients with pre-treatment ALT > 2 x ULN seroconverted.
Slovenian: Pri bolnikih s povečanimi vrednostmi ALT se je serokonverzija HBeAg povečala; do serokonverzije je prišlo pri 77 % (20/26) bolnikov, ki so imeli pred zdravljenjem ALT > 2x ZMN (zgornja meja normale).
English: • an increase in the level of some liver enzymes (transaminases), which may be a sign of inflammation or damage in the liver.
Slovenian: • zvišanje vrednosti nekaterih jetrnih encimov (transaminaz); to je lahko znak vnetja jeter.
English: Serum ALT and HBV DNA levels should be followed regularly after treatment discontinuation to detect any late virological relapse.
Slovenian: Po prenehanju zdravljenja je treba redno kontrolirati koncentracijo ALT in HBV DNA v serumu, da bi odkrili morebiten pozni virološki relaps.
English: HBV viral subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have been identified with extended therapy.
Slovenian: Z razširitvijo zdravljenja so bile odkrite podskupine virusa HBV (YMDD mutant HBV) z zmanjšano občutljivostjo za lamivudin.
English: Contains amongst others: sugar (sucrose), preservatives: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)
Slovenian: Med drugim vsebuje tudi: sladkor (saharoza), konzervansa: metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216).
English: Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction.
Slovenian: Študije pri bolnikih z oslabljenim delovanjem ledvic kažejo, da renalna disfunkcija prizadene izločanje lamivudina.
English: In patients with YMDD mutant HBV, 41/82 (50 %) patients had improvement in liver inflammation and 40/56 (71 %) patients without YMDD mutant HBV had improvement.
Slovenian: Pri 41/82 (50 %) bolnikov z YMDD mutantom HBV in pri 40/56 (71 %) bolnikov brez YMDD mutanta HBV je prišlo do izboljšanja vnetnih sprememb jeter.
English: Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA.
Slovenian: Po prekinitvi zdravljenja hepatitisa B so opažali akutno poslabšanje hepatitisa, po navadi ugotovljeno z zvišanjem serumske ALT in ponovnim pojavom HBV DNA.
English: Any child exposed in utero to nucleoside and nucleotide analogues, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in cases which have relevant signs or symptoms.
Slovenian: Vsakega otroka, ki je in utero izpostavljen nukleozidnim ali nukleotidnim analogom, je treba klinično in laboratorijsko spremljati.
English: Data available in patients undergoing intermittent haemodialysis (for less than or equal to 4 hrs dialysis 2-3 times weekly), indicate that following the initial dosage reduction of lamivudine to correct for the patient's creatinine clearance, no further dosage adjustments are required while undergoing dialysis.
Slovenian: do 3-krat tedensko), kažejo, da po začetnem zmanjšanju odmerka lamivudina in korekciji glede na bolnikov očistek kreatinina nadaljnje uravnave odmerka med dializo niso potrebne.
English: A common side effect which may show up in blood tests is:
Slovenian: Pogost neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je:
English: Lamivudine has no pharmacokinetic interaction with alpha-interferon when the two medicinal products are concurrently administered.
Slovenian: V primeru sočasne uporabe obeh zdravil lamivudin nima farmakokinetičnih interakcij z interferonom alfa.
English: ALT  3 x baseline value†
Slovenian: ALT ≥ 2 x osnovna vrednost ALT ≥ 3 x osnovna vrednost†
English: A very rare side effect (these may affect up to 1 in 10,000 people) is:
Slovenian: Zelo redek neželeni učinek (pojavi se lahko pri največ 1 od 10.000 bolnikov) je:
English: In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min.
Slovenian: Pri starejših bolnikih normalen proces staranja s spremljajočim upadanjem ledvične funkcije nima klinično pomembnega učinka na izpostavljenost lamivudinu, razen pri bolnikih z očistkom kreatinina
English: The active substance is lamivudine.
Slovenian: Učinkovina je lamivudin.
English: Stop taking Zeffix.
Slovenian: Nehajte jemati zdravilo Zeffix.
English: Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults.
Slovenian: Sočasna uporaba raztopine sorbitola (3,2 g; 10,2 g ; 13,4 g) z enkratnim odmerkom 300 mg (dnevni odmerek za odrasle z virusom HIV) lamivudina v peroralni raztopini, je pri odraslih povzročila od količine sorbitola odvisno zmanjšanje izpostavljenosti (AUC∞) lamivudinu za 14 %, 32 % oziroma 36 % ter zmanjšanje Cmax lamivudina za 28 %, 52 % in 55 %.
English: In patients who have YMDD mutant HBV, a switch to or addition of an alternative agent without cross-resistance to lamivudine based on therapeutic guideline should be considered (see section 5.1).
Slovenian: Pri bolnikih z YMDD mutantom HBV je treba skladno s smernicami za zdravljenje razmisliti o zamenjavi ali dodatku drugega zdravila, ki nima navzkrižne odpornosti proti lamivudinu (glejte poglavje 5.1).
English: Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com
Slovenian: GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 finland.tuoteinfo@gsk.com
English: Your doctor may prescribe a lower dose if you have problems with your kidneys.
Slovenian: Če imate težave z ledvicami, vam bo zdravnik morda predpisal nižji odmerek.
English: How to take Zeffix
Slovenian: Kako jemati zdravilo Zeffix
English: Improvement in bridging fibrosis occurred in 19/30 (63 %) patients without YMDD mutant and 22/44 (50 %) patients with the mutant.
Slovenian: Pri 19/30 (63 %) bolnikov brez YMDD mutanta in 22/44 (50 %) bolnikov z mutantom je prišlo do izboljšanja fibroze.
English: In patients without YMDD mutant HBV, 14/22 (64 %) showed improvement in necroinflammatory score and 1/22 (5 %) patients worsened compared to pre-treatment.
Slovenian: Pri bolnikih brez YMDD mutanta HBV se je pri 14/22 (64 %) pokazalo izboljšanje nekroznih in vnetnih sprememb, pri 1/22 (5 %) pa se je stanje v primerjavi s stanjem pred zdravljenjem poslabšalo.
English: Immunosuppressive treatments
Slovenian: Bolezni imunskega sistema
English: INFORMATION IN BRAILLE zeffix 100 mg
Slovenian: zeffix 100 mg
English: Blood and lymphatic system disorders Not known
Slovenian: Bolezni krvi in limfatičnega sistema:
English: Addition of 10 mg adefovir dipivoxil once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml.
Slovenian: 52-tedensko zdravljenje z lamivudinom v odmerku 100 mg in dodatkom 10 mg adefovirjevega dipivoksila enkrat dnevno je vrednosti HBV DNA v povprečju zmanjšalo za 4,6 log10 kopij/ml.
English: Don't stop taking Zeffix
Slovenian: Ne prenehajte jemati zdravila Zeffix
English: Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (less than 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age.
Slovenian: (manj kot 4 % koncentracije v materinem serumu) in se progresivno zmanjša do nezaznavne ravni, ko dojenček doseže 24 tednov starosti.
English: Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine.
Slovenian: Po prekinitvi zdravljenja z lamivudinom po serokonverziji HBeAg sta serološki odziv in klinična remisija običajno stanovitna.
English: Do not stop treatment with Zeffix without your doctor's advice.
Slovenian: Ne prekinjajte zdravljenja z zdravilom Zeffix, ne da bi se prej posvetovali z zdravnikom.
English: Exacerbations on treatment
Slovenian: Trajanje zdravljenja
English: Experience in patients with HBeAg positive CHB and compensated liver disease In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication [34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6pg/ml)}, normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 1618 % of patients), improved histology (38-52 % of patients had a  2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis.
Slovenian: Izkušnje pri HBeAg pozitivnih bolnikih s CHB in kompenzirano jetrno boleznijo V nadzorovanih študijah je enoletno zdravljenje z lamivudinom znatno zavrlo replikacijo HBV DNA [pri 34 do 57 % bolnikov je bila pod mejo dokazljivosti s testom (Abbott Genostics hibridizacijski test v raztopini, LLOD < 1,6 pg/ml)], normaliziralo aktivnost ALT (pri 40 do 72 % bolnikov), sprožilo serokonverzijo HBeAg (izginotje HBeAg ter pojav protiteles HBeAb z izginotjem HBV DNA [z običajnimi testi] pri 16 do 18 % bolnikov), izboljšalo histološko sliko (pri 38 do 52 % bolnikov se je Knodell-ov histološki indeks aktivnosti [HAI] znižal za ≥ 2 točki) in zmanjšalo progresijo fibroze (pri 3 do 17 % bolnikov) in progresijo v cirozo.
English: In patients with the mutant, 4/26 (15%) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pretreatment.
Slovenian: Pri bolnikih z YMDD mutantom se je pri 4/26 (15 %) pokazalo izboljšanje nekroznih in vnetnih sprememb, pri 8/26 (31 %) bolnikih pa se je stanje v primerjavi s stanjem pred zdravljenjem poslabšalo.
English: Those with HBV DNA levels greater than 200 copies/mL at 6 months (24 weeks) of lamivudine therapy had a 60 % chance of developing the YMDD mutant compared with 8 % of those with HBV DNA levels less than 200 copies/mL at 24 weeks of lamivudine therapy.
Slovenian: Tisti, ki so imeli po 6 mesecih (24 tednih) zdravljenja z lamivudinom koncentracijo HBV DNA večjo kot 200 kopij/ml, so imeli 60 % možnost za pojav mutanta YMDD, v primerjavi z 8 % možnostjo pojava pri tistih, s koncentracijo HBV DNA manj kot 200 kopij/ml po 24 tednih, medtem ko je bila ta možnost v primeru koncentracije HBV DNA manj kot 1000 kopij/ml 13 % po 24 tednih zdravljenja s lamivudinom (NUCB3009 in NUCB3018).
English: The clinical status of the patient and the adverse reaction profile of lamivudine should be borne in mind when considering the patient's ability to drive or operate machinery.
Slovenian: Pri ocenjevanju bolnikove sposobnosti za upravljanje vozil ali strojev je potrebno upoštevati klinično stanje bolnika in profil neželenih učinkov lamivudina.
English: INFORMATION IN BRAILLE zeffix 5 mg/ml
Slovenian: zeffix 5 mg/ml
English: An oral solution of Zeffix is available for people who need a lower than usual dose, or who can't take tablets.
Slovenian: Za osebe, ki potrebujejo manjši odmerek od običajnega ali ne morejo jemati tablet, je na voljo peroralna raztopina zdravila
English: * Zeffix oral solution containing 5 mg/ml lamivudine.
Slovenian: * Zdravilo Zeffix peroralna raztopina vsebuje 5 mg/ml lamivudina.